Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Molecular bacterial load assay (MBLA) rapidly quantifies viable Mycobacterium tuberculosis (Mtb) and may be useful for monitoring treatment response and treatment efficacy. We conducted a prospective study in 56 adults with pulmonary tuberculosis from whom 244 sputum samples were collected before and during the first month of treatment. We evaluated MBLA for early monitoring of bacterial burden and investigated bactericidal activities of first-line therapy in patients infected with drug susceptible and resistant isolates. Mtb loads measured by MBLA and culture were correlated after one-week (r = 0.56) and one-month (r = 0.73) of treatment. Correlations between culture and GeneXpert or microscopy were weaker during treatment. Mtb load by MBLA declined more rapidly than GeneXpert after one-week (2.73 Ct, P 

Original publication

DOI

10.1016/j.tube.2019.101864

Type

Journal article

Journal

Tuberculosis (Edinburgh, Scotland)

Publication Date

12/2019

Volume

119

Addresses

Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam.

Keywords

Sputum, Humans, Mycobacterium tuberculosis, Tuberculosis, Pulmonary, RNA, Bacterial, Antibiotics, Antitubercular, Early Diagnosis, Prognosis, Retrospective Studies, Adult, Middle Aged, Female, Male, Bacterial Load